LNTH Lantheus Holdings Inc

Lantheus to Present at the 2025 Truist Securities MedTech Conference

Lantheus to Present at the 2025 Truist Securities MedTech Conference

BEDFORD, Mass., June 10, 2025 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus”) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, today announced Brian Markison, Chief Executive Officer, will present at the 2025 Truist Securities MedTech Conference at 8:40 a.m. ET on Tuesday, June 17.

To access a live webcast of the presentation, please visit the Investors section of the Company’s website at . A replay of the webcast will be available on the Company’s website for at least 30 days following the live presentation.

About Lantheus

Lantheus is the leading radiopharmaceutical-focused company, delivering life-changing science to enable clinicians to Find, Fight and Follow disease to deliver better patient outcomes. Headquartered in Massachusetts with offices in New Jersey, Canada, Sweden and Switzerland, Lantheus has been providing radiopharmaceutical solutions for nearly 70 years. For more information, visit .

Contacts:

Mark Kinarney

Vice President, Investor Relations

978-671-8842

Melissa Downs

Executive Director, External Communications

646-975-2533



EN
10/06/2025

Underlying

LNTHLantheus Holdings Inc

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Lantheus Holdings Inc

 PRESS RELEASE
Free
LNTH Lantheus Holdin...

Lantheus Reports Second Quarter 2025 Financial Results and Provides Bu...

Lantheus Reports Second Quarter 2025 Financial Results and Provides Business Update Recorded second quarter 2025 worldwide revenue of $378.0 million, GAAP fully diluted earnings per share of $1.12, adjusted fully diluted earnings per share of $1.57 and free cash flow of $79.1 millionAnnounced FDA acceptance of NDA for new formulation for piflufolastat F 18 PSMA PET imaging agent with a PDUFA date of March 6, 2026Closed acquisition of Life Molecular Imaging in July, immediately expanding near- and long-term growth profile and commercial portfolio with Neuraceq® (florbetaben F 18 injection), ...

August 6, 2025 1 EN
 PRESS RELEASE
Free
LNTH Lantheus Holdin...

Lantheus Announces FDA Acceptance of NDA for New Formulation for Marke...

Lantheus Announces FDA Acceptance of NDA for New Formulation for Market-Leading PSMA PET Imaging Agent Designed to expand PSMA PET imaging access for patients by increasing batch size by ~50% and enhancing supply resiliencePDUFA date set for March 6, 2026 BEDFORD, Mass., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus”) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, today announced that the Food and Drug Administration (FDA) has accepted a New Dru...

August 6, 2025 1 EN
 PRESS RELEASE
Free
LNTH Lantheus Holdin...

Lantheus to Host Second Quarter 2025 Earnings Conference Call and Webc...

Lantheus to Host Second Quarter 2025 Earnings Conference Call and Webcast on August 6, 2025, at 8:00 a.m. Eastern Time BEDFORD, Mass., July 23, 2025 (GLOBE NEWSWIRE) -- (the “Company”) (NASDAQ: LNTH) today announced that it will host a conference call and webcast at 8:00 a.m. ET on Wednesday, August 6, 2025, to discuss its financial results and provide a business update for the second quarter of 2025. To access the conference call or webcast, participants should register online at . To avoid delays, we encourage participants to register fifteen minutes ahead of the scheduled start time....

July 23, 2025 1 EN
 PRESS RELEASE
Free
LNTH Lantheus Holdin...

Lantheus Completes Acquisition of Life Molecular Imaging and Appoints ...

Lantheus Completes Acquisition of Life Molecular Imaging and Appoints Dr. Ludger Dinkelborg as Head of R&D BEDFORD, Mass., July 22, 2025 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. ("Lantheus" or the "Company") (NASDAQ: LNTH), today announced the successful completion of its previously disclosed acquisition of Life Molecular Imaging Ltd. ("Life Molecular"), a subsidiary of Life Healthcare Group Holdings Ltd ("Life Healthcare"). As part of the acquisition, Ludger Dinkelborg, PhD, formerly CEO and Managing Director of Life Molecular Imaging, has been appointed Head of Research and Developme...

July 22, 2025 1 EN
 PRESS RELEASE
Free
LNTH Lantheus Holdin...

Lantheus Announces Presentations to be featured at the 2025 Society of...

Lantheus Announces Presentations to be featured at the 2025 Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting BEDFORD, Mass., June 11, 2025 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (the Company) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, announced the presentation of new data highlighting two oncology radiodiagnostic agents will be presented at the upcoming 2025 Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting, taking...

June 11, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch